MedTrace Logo

Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial

NCT01035450 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3206

Last updated 2015-12-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether the newly-approved everolimus-eluting stent is not inferior to the sirolimus-eluting stent in terms of the rate of target-lesion revascularization at 1-year and death or myocardial infarction at 3-year after stent implantation in the real world clinical practice.

Conditions

Interventions

DEVICE

Everolimus-eluting stent

Everolimus-eluting stent

DEVICE

Sirolimus-eluting stent

Sirolimus-eluting stent

Sponsors & Collaborators

  • Takeshi Morimoto

    lead OTHER

Principal Investigators

  • Takeshi Kimura, MD · Professor of Medicine, Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2014-03-31
Completion
2014-05-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01035450 on ClinicalTrials.gov